It has been proposed that the unique properties of ibogaine could be valuable in the treatment of various substance use disorders. However, previous research has found that ibogaine has an unfavourable cardiac safety profile. Researchers are hoping that derivatives of ibogaine can elicit the same effects but in a safer manner.
This is a phase I study that will assess the safety and tolerability of 18-MC, a non-hallucinogenic ibogaine derivative. During this Phase I study, participants will be given an escalating dose of 18-MC for up to seven days. After the dosing, participants will be followed up to 42 days later.
This trial has an estimate of 108 participants in a randomized doble blind with 3 phases: Screening, Enrollment and Follow-Up.